

20014. We gratefully acknowledge the technical help of Ms Karen Terry, Ms Kathy Dandridge, Mrs Shirley Livingston, Mrs Annette Matthews, and Mrs Terry Smith.

Requests for reprints should be addressed to: Professor Jordan U Gutterman, Department of Developmental Therapeutics, M D Anderson Hospital and Tumour Institute, 6723 Bertner Avenue, Houston, Texas 77030.

References

- 1 American Cancer Society, *Cancer Facts and Figures*. New York, American Cancer Society, 1975.
- 2 Cutler, S J, *Seminars in Oncology*, 1974, **1**, 91.
- 3 Greenspan, E M, *Journal of the Mount Sinai Hospital*, 1966, **33**, 435.
- 4 Canellos, G P, *et al*, *British Medical Journal*, 1974, **1**, 218.
- 5 Gottlieb, J A, *et al*, *Adriamycin Reviews*. Ghent, European Press Medikon, 1975.
- 6 Jones, S E, Durie, B G, and Salmon, S E, *Cancer (Philadelphia)*, 1975, **36**, 90.
- 7 Blumenschein, G R, Cardenas, J O, and Freireich, E J, *Proceedings of the American Society of Clinical Oncology*, 1974, **15**, 193.
- 8 Black, M M, Kerpe, S, and Speer, F D, *American Journal of Pathology*, 1953, **29**, 505.
- 9 Bloom, H J, Richardson, W W, and Field, J R, *British Medical Journal*, 1970, **3**, 181.
- 10 Gutterman, J U, Mavligit, G M, and Hersh, E M, *Medical Clinics of North America*, 1976, **60**, 441.
- 11 Gutterman, J U, *et al*, *New England Journal of Medicine*, 1974, **291**, 592.
- 12 Gutterman, J U, *et al*, *Lancet*, 1974, **2**, 1405.
- 13 Minow, R A, Benjamin, R S, and Gottlieb, J A, *Cancer Chemotherapy Reports*, 1975, **6**, 195.
- 14 Cutler, S J, in *Prognostic Factors in Breast Cancer*, ed A P Forrest and P B Kunkler, p 20. Edinburgh and London, Livingstone, 1968.
- 15 Friedell, H, *Journal of the National Cancer Institute*, 1974, **53**, 603.
- 16 Gehan, E A, *Biometrika*, 1965, **52**, 203.
- 17 Kaplan, E L, and Meier, P, *Journal of the American Statistical Association*, 1958, **53**, 457.
- 18 Brambilla, C, *et al*, *British Medical Journal*, 1976, **1**, 801.
- 19 Israel, L, and Edelstein, R, *Immunological Aspects of Neoplasia*, 26th symposium. Baltimore, Williams and Wilkins, 1975.
- 20 Rojas, A F, *et al*, *Lancet*, 1976, **1**, 211.
- 21 Oettgen, H F, *et al*, *Proceedings of the National Academy of Sciences*, 1974, **71**, 2319.
- 22 Fisher, B, Carbone, P, and Economou, S G, *New England Journal of Medicine*, 1975, **292**, 117.
- 23 Bonadonna, G, *et al*, *New England Journal of Medicine*, 1976, **294**, 405.
- 24 Mavligit, G M, *et al*, *Lancet*, 1976, **1**, 871.
- 25 Gutterman, J U, *et al*, *Lancet*, 1973, **1**, 1208.
- 26 Eilber, F R, *et al*, *New England Journal of Medicine*, 1976, **294**, 237.

Small intestinal transit in diabetics

J H B SCARPELLO, M GREAVES, G E SLADEN

British Medical Journal, 1976, **2**, 1225-1226

Summary

Small intestinal transit was assessed in diabetic patients and healthy controls by measuring the breath hydrogen appearance time after the ingestion of lactulose. Transit in diabetics with autonomic neuropathy was significantly slower than in diabetics without neuropathy and controls. Delayed transit is probably due to vagal denervation. These slower transit times would allow bacteria to proliferate, which might explain why some diabetics have diarrhoea. The test cannot be used in patients with bacteria in the small bowel because these may metabolise lactulose and release hydrogen prematurely.

Introduction

Gut symptoms in diabetics are usually associated with autonomic neuropathy.¹ Diabetic diarrhoea may sometimes be associated with small intestinal bacterial overgrowth, and symptoms can be relieved by antibiotics.^{2,3} Bacterial colonisation of the small bowel may result from changed intestinal motility.

Transit through the small intestine is difficult to study, although various methods have been described.⁴ Recently Bond and Levitt have advocated measuring the breath hydrogen appearance time after the ingestion of a non-absorbable carbo-

hydrate.⁵ This simple non-invasive technique measures the time taken for a bolus of the carbohydrate to reach bacteria in the ileocaecal region.

We have used this technique to compare small intestinal transit times in normal people and diabetics with and without autonomic neuropathy.

Patients and methods

Twelve well-controlled, insulin-dependent diabetics (mean age 45 years) were studied together with eight healthy controls matched for age and sex. None were receiving any drugs apart from insulin. The diabetics were assessed for evidence of autonomic neuropathy.⁶ None of the diabetics had diarrhoea, and all had had normal results in the ¹⁴C-glycocholic acid test, a sensitive test of bacterial deconjugation of bile acids in the small bowel.³ This was considered important because small-bowel bacteria can metabolise lactulose⁷ and would release hydrogen prematurely, invalidating the hydrogen test as a measure of small-bowel transit. To assess the validity of the hydrogen test two additional patients were studied: one had multiple jejunal diverticula before and after a course of tetracycline; the other was a diabetic with diarrhoea, a positive ¹⁴C-glycocholic acid test result, and a previous symptomatic response to antibiotics (metronidazole).³

After an overnight fast all subjects were given a solution of lactulose to drink (13 g lactulose as Duphalac syrup (20 ml) diluted with water to 130 ml). Breath samples were obtained every 10 minutes by end-expiratory sampling⁷ and analysed for hydrogen content using the apparatus described by Bergman *et al*.⁸ Sampling was continued with the subject inactive until a definite and sustained rise in breath hydrogen concentration was observed. This point was defined as the hydrogen appearance time.

Results

Six of the diabetics had good evidence of changed autonomic function in addition to a clinical history suggestive of autonomic

University Department of Medicine, Royal Hospital, Sheffield S1 3SR

J H B SCARPELLO, MB, MRCP, research assistant

M GREAVES, MB, MRCP, registrar

G E SLADEN, DM, FRCP, senior lecturer (now consultant physician, Guy's Hospital, London)

neuropathy. The remaining diabetics had normal autonomic function and were free of other complications.

The hydrogen appearance times for each subject in the three groups are shown in fig 1. No significant differences were observed, between diabetics without autonomic neuropathy (mean=69.8 min) and controls (mean=70.8 min). The diabetics with autonomic neuropathy, however, had a significantly delayed hydrogen appearance time (mean=140.2 min) compared with the controls ($P < 0.01$) and the other diabetics ($P < 0.01$) (Wilcoxon sum of ranks test). Repeat studies were performed in six subjects (see table). The correlation between both studies for all subjects was significant ($P < 0.01$; Spearman rank test).

A typical graph of breath hydrogen output is shown in fig 2. This also shows the pattern of hydrogen appearance in the patient with jejunal diverticula before and after antibiotics. The very early and rapid appearance of hydrogen indicated bacterial overgrowth in

the upper small intestine. After antibiotics no rise in breath hydrogen output was observed, indicating inhibition of bacteria in the colon as well as in the upper small intestine. A similar pattern was observed in the single diabetic with evidence of bacterial overgrowth in the small gut.

Discussion

It is difficult to investigate transit through the small intestine, and studies in diabetics have been few. McNally *et al.*,⁹ using balloon kymography, showed reduced intestinal motility in diabetics with autonomic neuropathy compared with values in diabetics without neuropathy and controls. The findings of radiological studies vary, some reporting an increased transit time, others a decrease.¹⁰

The use of the breath hydrogen appearance time provides a simple method of estimating the transit time of a bolus of fluid through the small intestine. The rise in the amount of breath hydrogen observed when the non-absorbed carbohydrate reaches the colonic bacteria is easily measured. Reproducibility in this series was good, and our results for normal controls were similar to those of Bond and Levitt.¹¹ The transit time depends on the quantity of lactulose given and cannot be applied to the transit of normal postprandial intestinal contents.

Our results strongly support the concept that small intestinal transit is delayed in diabetics with autonomic neuropathy. Slow intestinal transit could allow bacteria to proliferate in the lumen and this seems to explain diarrhoea in some diabetics.³ Unfortunately, the test is invalidated by the presence of small-gut bacteria capable of metabolising lactulose. The diabetics we studied had no evidence of bacterial overgrowth in the small intestine in that they all had negative ¹⁴C-glycocholic acid tests and had normal or delayed rather than premature excretion of hydrogen.

We would speculate that diabetics with bacterial overgrowth have even more sluggish small intestinal transit, but we cannot prove this with the present method. These findings contrast with those in a study in which we failed to show any significant delay in the gastric emptying of solid meals in diabetics with autonomic neuropathy.⁶ All three diabetics with the longest hydrogen appearance times had normal gastric emptying rates. Thus possibly, whereas slow intestinal transit is probably caused by vagal denervation, the stomach can empty solid meals at a normal rate even when it is deprived of some of its vagal supply.

We would like to thank Dr I Bergman for invaluable help, Dr D R Cullen for access to patients, and Drs T C G Smith and K S Liem of Duphar Laboratories for supplying the lactulose and for providing financial assistance.

JHBS is supported by a research grant from the Trustees of the former United Sheffield Hospitals.

References

- ¹ Rundles, R W, *Medicine*, 1945, **24**, 111.
- ² Malins, J M, and French, J M, *Quarterly Journal of Medicine*, 1957, **26**, 467.
- ³ Scarpello, J H B, *et al*, *British Medical Journal*, 1976, **2**, 673.
- ⁴ Waller, S L, *Gut*, 1975, **16**, 372.
- ⁵ Bond, J H, and Levitt, M D, *Journal of Laboratory and Clinical Medicine*, 1975, **85**, 546.
- ⁶ Scarpello, J H B, *et al*, *British Medical Journal*, 1976, **2**, 671.
- ⁷ Metz, G, *et al*, *Lancet*, 1976, **1**, 668.
- ⁸ Bergman, I, Coleman, J E, and Evans, D, *Chromatographia*, 1975, **8**, 581.
- ⁹ McNally, E F, Reinhard, A E, and Schwartz, P E, *American Journal of Digestive Diseases*, 1969, **14**, 163.
- ¹⁰ Whalen, G E, Soergel, K H, and Geenen, J E, *Gastroenterology*, 1969, **56**, 1021.
- ¹¹ Bond, J H, and Levitt, M D, *Journal of Clinical Investigation*, 1972, **51**, 1219.




FIG 1—Hydrogen appearance times.

Reproducibility studies on hydrogen appearance time (minutes)

Subject No . .	Controls			Diabetics		
	1	2	3	4	5	6
First study . .	65	100	65	102	184	143
Second study . .	70	95	60	110	186	130




FIG 2—Hydrogen excretion in normal subject and patient with jejunal diverticulosis before and after antibiotics.